Study Results from Tubingen University Provide New Insights into Breast Cancer (Implementation and Evaluation of a Breast Cancer Disease Model Using Real-World Claims Data in Germany from 2010 to 2020): Oncology – Breast Cancer

2024 APR 26 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Investigators publish new report on breast cancer. According to news reporting out of Tubingen, Germany, by NewsRx editors, research stated, “Breast cancer is the leading cause of cancer-related mortality among women in Germany and worldwide.”

Financial supporters for this research include Aok Baden-wuerttemberg.

The news journalists obtained a quote from the research from Tubingen University: “This retrospective claims data analysis utilizing data from AOK Baden-Wuerttemberg, a major statutory German health insurance provider, aimed to construct and assess a real-world data breast cancer disease model. The study included 27,869 female breast cancer patients and 55,738 age-matched controls, analyzing data from 2010 to 2020. Three distinct breast cancer stages were analyzed: Stage A (early breast cancer without lymph node involvement), Stage B (early breast cancer with lymph node involvement), and Stage C (primary distant metastatic breast cancer). Tumor subtypes were estimated based on the prescription of antihormonal or HER2-targeted therapy. The study established that 77.9% of patients had HR+ breast cancer and 9.8% HER2+; HR+/HER2- was the most common subtype (70.9%). Overall survival (OS) analysis demonstrated significantly lower survival rates for stages B and C than for controls, with 5-year OS rates ranging from 79.3% for stage B to 35.4% for stage C.”

According to the news reporters, the research concluded: “OS rates were further stratified by tumor subtype and stage, revealing varying prognoses. Distant recurrence-free survival (DRFS) analysis showed higher recurrence rates in stage B than in stage A, with HR-/HER2- displaying the worst DRFS. This study, the first to model breast cancer subtypes, stages, and outcomes using German claims data, provides valuable insights into real-world breast cancer epidemiology and demonstrates that this breast cancer disease model has the potential to be representative of treatment outcomes.”

For more information on this research see: Implementation and Evaluation of a Breast Cancer Disease Model Using Real-World Claims Data in Germany from 2010 to 2020. Cancers, 2024,16(8). (Cancers - http://www.mdpi.com/journal/cancers/). The publisher for Cancers is MDPI AG.

A free version of this journal article is available at https://doi.org/10.3390/cancers16081490.

Our news editors report that additional information may be obtained by contacting Dominik Dannehl, Department of Women’s Health, Tubingen University, 72076 Tubingen, Germany. Additional authors for this research include Alexandra von Au, Tobias Engler, Lea Louise Volmer, Raphael Gutsfeld, Johannes Felix Englisch, Markus Hahn, Sabine Hawighorst-Knapstein, Ariane Chaudhuri, Armin Bauer, Markus Wallwiener, Florin-Andrei Taran, Diethelm Wallwiener, Sara Yvonne Brucker, Stephanie Wallwiener, Andreas Daniel Hartkopf, Tjeerd Maarten Hein Dijkstra.

ORCID is an identifier for authors and includes bibliographic information. The following is ORCID information for the authors of this research: Dominik Dannehl (http://orcid.org/0000-0002-7653-8283), Alexandra von Au (http://orcid.org/0000-0001-7649-4914), Tobias Engler (http://orcid.org/0000-0002-8063-2053), Johannes Felix Englisch (http://orcid.org/0009-0005-5061-2042), Florin-Andrei Taran (http://orcid.org/0000-0001-7384-2928), Diethelm Wallwiener (http://orcid.org/0000-0002-4635-5283), Sara Yvonne Brucker (http://orcid.org/0000-0001-8588-1094), Andreas Daniel Hartkopf (http://orcid.org/0000-0003-1227-1118), Tjeerd Maarten Hein Dijkstra (http://orcid.org/0000-0002-4450-701X).

(Our reports deliver fact-based news of research and discoveries from around the world.)